FDA Accepts Amgen's Supplemental New Drug Application For Otezla® For Adults With Mild-To-Moderate Plaque Psoriasis Biotech Investing
Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference Biotech Investing
BLU Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BELLUS Health Inc. Investors of Class Action and Lead Plaintiff Deadline: May 17, 2021 Biotech Investing
Wellteq Receives OTC Listed Trading Symbol WTEQF and Announces Application to Up List on OTCQB Biotech Investing
Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology's 70th Annual Scientific Session Biotech Investing
BLU Looming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BELLUS Health Inc. Investors of Class Action and Lead Plaintiff Deadline: May 17, 2021 Biotech Investing
Naturally Splendid Announces CANEX Foods As Master Distributor And Initial Purchase Order Biotech Investing
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma Biotech Investing
ROSEN, A TOP RANKED LAW FIRM, Encourages BELLUS Health Inc. Investors with Losses over $100K to Secure Counsel Before Important May 17 Deadline in Securities Class Action - BLU Biotech Investing
